MXC.L

MGC Pharmaceuticals Limited
Stock Exch Notice - Suspension - MGC Pharmaceuticals Limited
3rd April 2024, 06:30
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0236J
London Stock Exchange Notice
03 April 2024
 

NOTICE

 

03/04/2024 7:30am

 

TEMPORARY SUSPENSION OF TRADING ON MAIN MARKET - STANDARD SEGMENT

 

MGC PHARMACEUTICALS LIMITED

 

At the request of the company, trading on Main Market - Standard Segment for the under-mentioned security has been temporarily suspended from 03/04/2024 7:30am.

 

ORDINARY SHARES OF NO PAR VALUE, FULLY PAID (DI)

(BK70NQ9)

(AU000000MXC6)

 

If you have any queries relating to the above, please contact the company's broker on +44 203 179 5300.

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
EXCDZGGDDZGGDZM]]>
TwitterFacebookLinkedIn